FIELD: medicine, pharmaceutics.
SUBSTANCE: there are described new compounds of general formula [I]: 
or their pharmacologically acceptable salts, wherein R1 is C1-6 alkyl; R2 is C1-6 alkoxy; m and n mean 1; W means N; the ring A represents fragments of formula 
, 
or 
that can be substituted; X1 is a single bond, C1-6 alkylene group or -C(O)NR3-, wherein R3 is hydrogen, C1-6 alkyl or phenyl; and the ring B represents fragments of formula [5]-[11]: 
that can be substituted, and a pharmaceutical composition containing them.
EFFECT: new compounds possess activity inhibiting the amyloid beta production, and are effective as a therapeutic agent for treating an Aβ-caused disease, such as Alzheimer disease or Down syndrome.
10 cl, 48 tbl, 399 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PIPERIDINE DERIVATIVES | 2011 |
|
RU2554353C2 |
| ENZYMES INHIBITION | 2013 |
|
RU2638537C2 |
| KINASE INHIBITORS | 2013 |
|
RU2637944C2 |
| NAPHTHYRIDIN DERIVATIVES AS ANTAGONISTS OF ALPHA V BETA 6 INTEGRIN FOR TREATING, IN PARTICULAR, FIBROTIC DISEASES | 2015 |
|
RU2692775C2 |
| PYRIDAZINE DERIVATIVES AS RORc MODULATORS | 2017 |
|
RU2757571C2 |
| TETRAHYDROTRIAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE | 2012 |
|
RU2622643C2 |
| TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATING SKIN DISEASES | 2009 |
|
RU2544011C2 |
| THIENOPYRIMIDINE COMPOUNDS AND THEIR APPLICATION | 2004 |
|
RU2331648C2 |
| METHODS FOR PRODUCTION OF RACEMIC AMINOSUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE OR RACEMIC AMINOSUBSTITUTED 5,6,7,8-TETRAHYDROISOQUINOLINE, METHODS FOR SEPARATION AND RACEMIZATION THEREOF, METHODS FOR PRODUCTION OF KETOSUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE OR KETOSUBSTITUTED 5,6,7,8-TETRAHYDROISOQUINOLINE, METHOD FOR PRODUCTION OF ENANTIOMER PF CONDENSED BYCYCLIC RING SUBSTITUTED WITH PRIMARY AMINE, 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES | 2002 |
|
RU2308451C2 |
| HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND THEIR USING | 2001 |
|
RU2289581C2 |
